1) The patient, a 6-year-old female, presented with generalized petechiae and prolonged epistaxis. Laboratory results showed high white blood cell count with 46% blasts and 44% promyelocytes containing Auer rods, consistent with acute promyelocytic leukemia (APL).
2) She received induction therapy for APL per the TPOG-APL-2001 protocol including all-trans retinoic acid (ATRA) and chemotherapy. She experienced complications including fever, pleural effusion, and later pseudotumor cerebri, thought to be related to a drug-drug interaction between ATRA and fluconazole.
3) Her course
This presentation is about anemia of chronic disease, nowadays also called as anemia of Inflammation. I have dealt with anemia in CKD and malignancy in detail.
This presentation is about anemia of chronic disease, nowadays also called as anemia of Inflammation. I have dealt with anemia in CKD and malignancy in detail.
- A new version of this lecture is available at: https://www.slideshare.net/MohammedGawad/thrombotic-microangiopathy-tma-in-adults-and-acute-kidney-injury-dr-gawad
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Dr Abdullah Ansari
MBBS, MD Medicine
Aligarh Muslim University
Clinical case
Hemolytic Anemia
Intravascular vs extravascular hemolysis
Classification of hemolytic anemia
Approach to hemolysis
Patient history
Clinical features
Peripheral blood smear
Investigation
Treatment
Thrombocytopenia is generally defined as platelet count <150 × 109/L. It can occur due to several reasons, like decreased platelet production (e.g., inherited bone marrow failure syndromes, acquired aplastic anemia, leukemia), ineffective platelet production (myelodysplastic syndrome, megaloblastic anemia), increased destruction (ITP, HLH), increased consumption (DIC, TTP, HUS), sequestration (hypersplenism), or may be due to combination of multiple mechanisms described above.
During evaluating a case of thrombocytopenia, the first step is getting a detailed history and doing a proper clinical examination. Then the next step would be checking the other parameters of complete blood count (CBC), especially hemoglobin (Hb) and the total WBC count, complemented by a peripheral smear (PS) examination, which will clear many doubts and will help us pinpointing our diagnostic approach.
Many a times pseudo-thrombocytopenia is encountered in a PS due to platelet clumping by EDTA and can be rectified by collecting blood samples in a citrate or heparin vials or by doing a direct finger prick smear. Any accompanying cytopenia will expand the differential diagnosis and an isolated thrombocytopenia will further narrow it down. Presence of any additional abnormalities of red cells (megaloblasts) or white cells (presence of hyper-segmented neutrophils, atypical lymphoid/myeloid cells) could be present in megaloblastic anemia/MDS, leukemia respectively, while in the presence of fragmented red cells microangiopathic hemolytic anemia should always be ruled out by doing PT and aPTT (DIC, TTP, HUS). In case of isolated thrombocytopenia, the platelet morphology is also important. In many patients in India, especially in eastern region many people have large platelets with their normal platelet count around 100 × 109/L with normal platelet function (Harris platelet syndrome). However, presence of any abnormal platelet morphology along with a low platelet count may indicate a platelet function disorder (large platelets in Bernard Soulier syndrome/ Glanzmann thrombasthenia or small platelets in Wiskott-Aldrich syndrome), especially if encountered in early part of life during evaluation for bleeding symptoms. In case of isolated thrombocytopenia, presence of additional congenital anomalies may point out towards an inherited marrow failure syndrome, e.g. amegakayocytic thrombocytopenia. Exposure to certain drugs may result in isolated low platelet count, e.g., ceftriaxone, piperacillin, heparin. Presence of toxic changes in neutrophils may indicate sepsis related thrombocytopenia. By excluding all these, immune thrombocytopenia (ITP) to be thought as no specific tests or markers are available for this entity and its diagnosis is largely clinical. A further work up complemented by bone marrow examination and in few cases a platelet function test will definitely help in reaching the final diagnosis.
So, summarizing, in the evaluation of a case of thrombocytopenia, all the
Current Standards and New Directions in the Treatment of Acquired Thrombotic ...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
Gain insight and expertise in this presentation on acquired thrombotic thrombocytopenic purpura. Spero Cataland, MD, Professor of Clinical Internal Medicine and Director of Benign Hematology at The Ohio State University, will provide guidance on current treatment standards and will discuss emerging therapies with the potential to improve patient outcomes in aTTP.
STATEMENT OF NEED
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy with a rapid onset and progression and a mortality rate of 10% to 20% with prompt treatment. Onset of aTTP is characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, and a constellation of associated symptoms including hemorrhage, neurologic and renal manifestations, cardiac abnormalities, and mesenteric ischemia (Joly et al, 2017). Survivors of first aTTP events tend to have relapse events which need to be controlled. Rapid recognition and immediate appropriate treatment are critical for achieving optimized outcomes in aTTP. In this activity chaired by Spero Cataland, MD, Professor of Clinical Internal Medicine and Director of Benign Hematology at The Ohio State University, expert faculty will provide insightful guidance on current treatment standards and will discuss emerging therapies with the potential to improve patient outcomes in aTTP.
TARGET AUDIENCE
Hematology fellows, attending faculty, and other health care professionals involved in the treatment of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to
Evaluate the clinical and laboratory features of aTTP that can inform timely and accurate diagnosis
Discuss how ADAMTS13 activity can be used to guide the management of aTTP
Assess the mechanism of action, efficacy, and safety of novel anti-von Willebrand factor nanobodies in aTTP as elucidated by recent clinical trials
Evaluate novel treatment combinations and sequences with the potential to improve the outcomes of patients with aTTP
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Mu...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
Presented by leading expert Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, this slide deck will explore guidance on current standards and new directions in newly diagnosed multiple myeloma.
STATEMENT OF NEED
An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, including anti-CD38 antibodies, has provided numerous therapeutic options for newly diagnosed multiple myeloma. However, the optimal selection of induction therapy and subsequent treatment sequencing for individual patients remains a challenge. Additionally, factors including age, frailty, comorbidities, transplant eligibility, treatment-related toxicities, and supportive care needs complicate treatment decisions (Costello et al, 2022). This hematology/oncology fellows lecture series will explore expert guidance on current standards and new directions in newly diagnosed multiple myeloma.
TARGET AUDIENCE
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with multiple myeloma.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
Assess guideline-recommended treatment combination and sequencing strategies in NDMM
Evaluate the role of minimal residual disease (MRD) assessment in NDMM treatment
Review the mechanism of action, efficacy, and safety of anti-CD38 monoclonal antibodies in the treatment of NDMM
Discuss strategies to monitor and manage treatment-related toxicities and optimize survivorship care
Venous Thromboembolism in the Cancer Patientlarriva
Cancer patients are at an increased risk of venous thromboembolism. There have been several guidelines published on the topic from the American College of Chest Physicians (ACCP), the American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN). Although they agree on some issues regarding prophylaxis and treatment there are several areas that vary. This presentation covers the varying recommendations and the areas of consensus (yellow boxes) among the guidelines while using a patient case to guide their interpretation.
Eddy Wouters, APL Logistics on '3PL Branding & Marketing'eyefortransport
Eddy Wouters, VP Logistics Europe, APL Logistics gets many laughs and lots of good feedback as he speaks on '3PL Branding & Marketing' at the 7th European 3PL Summit in Brussels, November 25th 2009.
To download all of the slides from the conference for free visit www.3PLsummit.com/eu_2009ppts
Slides were presented via a poster board in a class symposium of cancer genes. I reviewed primary literature to present the structure and function of cancer gene Retinoic Acid Receptor Alpha and its implications in Acute Promyelocytic Leukemia.
- A new version of this lecture is available at: https://www.slideshare.net/MohammedGawad/thrombotic-microangiopathy-tma-in-adults-and-acute-kidney-injury-dr-gawad
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Dr Abdullah Ansari
MBBS, MD Medicine
Aligarh Muslim University
Clinical case
Hemolytic Anemia
Intravascular vs extravascular hemolysis
Classification of hemolytic anemia
Approach to hemolysis
Patient history
Clinical features
Peripheral blood smear
Investigation
Treatment
Thrombocytopenia is generally defined as platelet count <150 × 109/L. It can occur due to several reasons, like decreased platelet production (e.g., inherited bone marrow failure syndromes, acquired aplastic anemia, leukemia), ineffective platelet production (myelodysplastic syndrome, megaloblastic anemia), increased destruction (ITP, HLH), increased consumption (DIC, TTP, HUS), sequestration (hypersplenism), or may be due to combination of multiple mechanisms described above.
During evaluating a case of thrombocytopenia, the first step is getting a detailed history and doing a proper clinical examination. Then the next step would be checking the other parameters of complete blood count (CBC), especially hemoglobin (Hb) and the total WBC count, complemented by a peripheral smear (PS) examination, which will clear many doubts and will help us pinpointing our diagnostic approach.
Many a times pseudo-thrombocytopenia is encountered in a PS due to platelet clumping by EDTA and can be rectified by collecting blood samples in a citrate or heparin vials or by doing a direct finger prick smear. Any accompanying cytopenia will expand the differential diagnosis and an isolated thrombocytopenia will further narrow it down. Presence of any additional abnormalities of red cells (megaloblasts) or white cells (presence of hyper-segmented neutrophils, atypical lymphoid/myeloid cells) could be present in megaloblastic anemia/MDS, leukemia respectively, while in the presence of fragmented red cells microangiopathic hemolytic anemia should always be ruled out by doing PT and aPTT (DIC, TTP, HUS). In case of isolated thrombocytopenia, the platelet morphology is also important. In many patients in India, especially in eastern region many people have large platelets with their normal platelet count around 100 × 109/L with normal platelet function (Harris platelet syndrome). However, presence of any abnormal platelet morphology along with a low platelet count may indicate a platelet function disorder (large platelets in Bernard Soulier syndrome/ Glanzmann thrombasthenia or small platelets in Wiskott-Aldrich syndrome), especially if encountered in early part of life during evaluation for bleeding symptoms. In case of isolated thrombocytopenia, presence of additional congenital anomalies may point out towards an inherited marrow failure syndrome, e.g. amegakayocytic thrombocytopenia. Exposure to certain drugs may result in isolated low platelet count, e.g., ceftriaxone, piperacillin, heparin. Presence of toxic changes in neutrophils may indicate sepsis related thrombocytopenia. By excluding all these, immune thrombocytopenia (ITP) to be thought as no specific tests or markers are available for this entity and its diagnosis is largely clinical. A further work up complemented by bone marrow examination and in few cases a platelet function test will definitely help in reaching the final diagnosis.
So, summarizing, in the evaluation of a case of thrombocytopenia, all the
Current Standards and New Directions in the Treatment of Acquired Thrombotic ...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
Gain insight and expertise in this presentation on acquired thrombotic thrombocytopenic purpura. Spero Cataland, MD, Professor of Clinical Internal Medicine and Director of Benign Hematology at The Ohio State University, will provide guidance on current treatment standards and will discuss emerging therapies with the potential to improve patient outcomes in aTTP.
STATEMENT OF NEED
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy with a rapid onset and progression and a mortality rate of 10% to 20% with prompt treatment. Onset of aTTP is characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, and a constellation of associated symptoms including hemorrhage, neurologic and renal manifestations, cardiac abnormalities, and mesenteric ischemia (Joly et al, 2017). Survivors of first aTTP events tend to have relapse events which need to be controlled. Rapid recognition and immediate appropriate treatment are critical for achieving optimized outcomes in aTTP. In this activity chaired by Spero Cataland, MD, Professor of Clinical Internal Medicine and Director of Benign Hematology at The Ohio State University, expert faculty will provide insightful guidance on current treatment standards and will discuss emerging therapies with the potential to improve patient outcomes in aTTP.
TARGET AUDIENCE
Hematology fellows, attending faculty, and other health care professionals involved in the treatment of patients with acquired thrombotic thrombocytopenic purpura (aTTP).
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to
Evaluate the clinical and laboratory features of aTTP that can inform timely and accurate diagnosis
Discuss how ADAMTS13 activity can be used to guide the management of aTTP
Assess the mechanism of action, efficacy, and safety of novel anti-von Willebrand factor nanobodies in aTTP as elucidated by recent clinical trials
Evaluate novel treatment combinations and sequences with the potential to improve the outcomes of patients with aTTP
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Mu...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
Presented by leading expert Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, this slide deck will explore guidance on current standards and new directions in newly diagnosed multiple myeloma.
STATEMENT OF NEED
An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, including anti-CD38 antibodies, has provided numerous therapeutic options for newly diagnosed multiple myeloma. However, the optimal selection of induction therapy and subsequent treatment sequencing for individual patients remains a challenge. Additionally, factors including age, frailty, comorbidities, transplant eligibility, treatment-related toxicities, and supportive care needs complicate treatment decisions (Costello et al, 2022). This hematology/oncology fellows lecture series will explore expert guidance on current standards and new directions in newly diagnosed multiple myeloma.
TARGET AUDIENCE
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with multiple myeloma.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
Assess guideline-recommended treatment combination and sequencing strategies in NDMM
Evaluate the role of minimal residual disease (MRD) assessment in NDMM treatment
Review the mechanism of action, efficacy, and safety of anti-CD38 monoclonal antibodies in the treatment of NDMM
Discuss strategies to monitor and manage treatment-related toxicities and optimize survivorship care
Venous Thromboembolism in the Cancer Patientlarriva
Cancer patients are at an increased risk of venous thromboembolism. There have been several guidelines published on the topic from the American College of Chest Physicians (ACCP), the American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN). Although they agree on some issues regarding prophylaxis and treatment there are several areas that vary. This presentation covers the varying recommendations and the areas of consensus (yellow boxes) among the guidelines while using a patient case to guide their interpretation.
Eddy Wouters, APL Logistics on '3PL Branding & Marketing'eyefortransport
Eddy Wouters, VP Logistics Europe, APL Logistics gets many laughs and lots of good feedback as he speaks on '3PL Branding & Marketing' at the 7th European 3PL Summit in Brussels, November 25th 2009.
To download all of the slides from the conference for free visit www.3PLsummit.com/eu_2009ppts
Slides were presented via a poster board in a class symposium of cancer genes. I reviewed primary literature to present the structure and function of cancer gene Retinoic Acid Receptor Alpha and its implications in Acute Promyelocytic Leukemia.
Oncologic emergency
Abrupt release of intracellular contents in high quantity
Prophylaxis and treatment aimed at assisting body to rid electrolyte excess
May be spontaneous or as a result of anti- cancer therapy
Characterized by: elevated K+ ,PO4 and uric acid with resultant decrease in calcium.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
NVBDCP.pptx Nation vector borne disease control program
All-trans retinoic acid related complications in a patient with acute promyelocytic leukemia
1. All-trans retinoic acid related
complications in a patient with acute
promyelocytic leukemia
1
2013. 05. 16
臨床藥學與藥物科技所 陳秋縈
指導老師 鄭兆能 醫師
Case report
2. Patient profile
2
Name 戴XX Admission date 2013/02/18
Age 6 y/o HT 124.3cm (50-75th%)
Gender female BW 25.8kg (75-90th%)
BSA 0.94 Allergy history NKDA
Past history
• Hospitalization: pneumonia 3y/o
Chief complaint
• Suffered from Generalized petechiae for recent one week
• Prolonged epistaxis this morning
She was referred from ENT LMD, and AOM left side was found at LMD
Physical examination and ROS
• T/P/R: 36.4/148/24 BP: 117/88mmHg
• Petechiae over trunk and extremities, especial anterior neck
• Ear drum: left side injected
3. Lab data on 2/18
3
檢驗名稱 參考值 單位 結果
WBC 4.27-13.18 10^3/μL H 52.8
RBC 3.84-5.01 10^6/μL L 2.97
Hb 10.2-13.2 g/dL L 8.2
Hct 30.9-37.9 % L 23.9
MCV 72.3-87.6 fl 80.7
MCH 23.7-29.5 pg 27.5
MCHC 33.2-35.2 g/dL 34.1
RDW 12.2-15.1 % 13.1
Plt 189-459 10^3/μL L 20
Blast % 46
Pro % 44
Myelo % 0
Meta % 0
Band % 0
Seg 22.4-69 % 1
Eos 0-3.6 % 0
Baso 0-0.7 % 0
Mono 4.1-11.4 % 0
Lymph 18.1-68.6 % 9
Aty-lym % 0
NRBC /Count WBCs 0
*Auer rods in the cytoplasm as found
檢驗名稱 參考值 單位 結果
CRP 0-8 mg/L H 32.2
FIB 276-471 mg/dL L 238.5
BIL-T 0.2-1.4 mg/dL 0.7
ALK-P 30-110 U/L H 147
CA 8.6-10.1 mg/dL 9.8
P 2.5-4.5 mg/dL 4.1
BIL-D 0-0.3 mg/dL 0.3
NA 135-148 mmol/L 145
K 3.5-5 mmol/L 4.5
BUN 7-21 mg/dL 12
CREA 0.6-1.2 mg/dL 0.46
URIC 2-6 mg/dL 6.3
AST 0-39 U/L 35
ALT 0-54 U/L 24
LD 100-200 U/L H 866
Impression:
1. Lab: Blast and promyelocyte with auer rods was
found from peripheral blood
Suspect acute leukemia
2. Acute otitis media (AOM)
APTT 26-38 secs 28
MNAPTT secs 32.7
PT 9.4-12.5 secs H 16
PT(MNPT) secs 10.5
4. Hospital course-1
4
Date Event Management
2/18 • WBC: 52800/μL, Blast: 46%, Pro: 44%
Blast and promyelocyte with auer rods was
found
Acute leukemia was suspected (APL)
• Perform bone marrow aspiration, biopsy and
chromosome for diagnosis
night • Fever up to 39.5, CRP: 27.4 mg/L
Suspect AOM, r/o tumor fever
• B/C, UA
• Unasyn, Gentamicin
• Acetaminophen, Diclofenac EM
2/20 • BM biopsy and cytogenetic report:
t(15,17), PML-RAR alpha: positive
Acute promyelocytic leukemia (APL, M3)
Start TPOG-APL-2001 induction therapy
• ATRA 20mg QD 10mg HS
2/21 • Fever, pleural effusion, hyperleukocytosis
CXR: bilateral pleural effusion, no dyspnea
BT: 38.4
WBC: 52800→ 96600/μL
• Idarubicin 8.5 mg IVD 2/21-23
MTX IT 2/21
Granisetron 3mg IVD before CT
• Dexamethasone 10mg q12h x 3 days
for prevent DS (differentiation syndrome)
2/22 • Fever subside, no pleural effusion, dyspnea
• AOM improved
• Peripheral edema with BW gain
(25.8 28.8kg)
• Furosemide 10mg ivd stat
5. Hospital course-2
5
Date Event Management
2/24 • WBC: 71200→ 15900/μL • Taper dexamethasone 5mg qd
2/25 • No fever for 3 days • DC ABX
2/26 • WBC↓: 1100/μL • DC dexamethasone
2/28 • BT: 39, WBC: 1300 /μL
Neutropenic fever
• CRP: 27.6 mg/L
• B/C from peripheral and CVP
• Amikacin, Cefazolin, Piperacillin
3/1 • UA, CXR: normal
• WBC: 500/μL
• Oral ulcer, gingiva swelling
Suspect HSV or oral infection
• Acyclovir 250 mg IVD q8h
• Nystatin 1# qid when
3/2 • CRP: 62.9 mg/L, Still fever
• Blood culture from CVP: GPC
Highly suspect CVP related infection
• Remove CVP
• Shift cefazolin to Vancomycin (3/2-8)
3/4 • Persist high fever and elevated CRP • Fluconazole 250 mg qd
3/5 • Blood culture from CVP: CoNS
• CRP: 79.9 mg/L
• Persist neutropenic fever
• CXR: R’t lung infiltration
• Shift piperacillin, amikacin to meropenen
Neutropenic
Fever
6. Hospital course-3
6
Date Event Management
3/8 • Procalcitonin: 0.324 ng/ml • DC vancomycin after 7-day-use
• Metronidazole 200 mg q6h ivd
• Baktar 1# bid 1,3,5
3/10 • HTN was noted 150/99mmHg
3/13 • Fever subside, CRP↓ 161.3 45mg/L
• Visual diplopia(+), papilloedema(+), N/V
Suspect ATRA and fluconazole DDI related
pseudotumor cerebri
• DC metronidazole, meropenem (9d), acyclovir
(14d) de-escalate to penicillin, ceftazidime
• Discontinued ATRA
• Acetazolamide 125mg qd
Mannitol 6mg q8h ivd
Dexamethasone 7.5 mg q6h ivd for IICP
• CSF study or brain image survey
3/16 • Hypertension improved, still blurred vision
• Stable condition
• Discharge
Nystatin 1# qid
Dexamethasone 4mg bid po
Acetazolamide 125mg qd
Augmentin 1# bid
3/18 • Diplopia improved
Fever
9. Acute myeloid leukemia (AML)
9
AML is characterized by a clonal proliferation of hematopoietic
progenitor with reduce ability to differentiate into mature
elements
Leukemic blasts or immature forms in bone marrow and periphery
RBCs, platelets, and neutrophils
Anemia, bleeding, infection
Our patient
• Generalized petechiae
• Prolonged epistaxis
• Fever, suspect AOM
10. Classification of acute myeloid leukemia
Blood 2009;114:937 10
APL is a biologically and clinically distinct variant of AML
• French American British (FAB) classification: M3 subtype of AML
• WHO 2008 classification: APL with t(15;17)(q22;q12), (PML/RAR)
(Classified based upon morphology, immunophenotype, genetics, and clinical features)
4 major subtypes Examples
With recurrent genetic abnormalities t(8;21); inv(16); t(15;17); 11q23 anomalies
With myelodysplasia-related features Antecedent myelodysplastic syndrome (MDS)
Therapy-related AML Alkylating agents or topoisomerase inhibitors
Not otherwise specified With minimal differentiation, maturation,
myelomonocytic, monoblastic, erythroid
11. Pathogenesis
Nat Med 2001 Jun;7(6):680 11
Translocation of retinoic acid
receptor gene (RARα) to
promyelocytic gene (PML) leading
to chimeric oncogene PML-RARα
PML-RARa fusion protein forms a homodimer
Binds to RARα target genes and ehnance
co-repressors binding
Blocked differentiation and enhanced
self-renewal of the promyelocytes
PML-RARa fusion protein
12. Epidemiology of APL
Hematol Oncol Clin North Am. 2009 Aug;23(4):633-54
Blood. 2009 Feb 26;113(9):1875-91
12
Who is most affected: Most common in young adults
Very uncommon in children < 10 years old
Incidence increases during teen years
Incidence plateaus in early adulthood and remains steady up to about age
60 years
Incidence decreases after age 60 years
Incidence/Prevalence:
Rare
5%-8% of all AML
4%-8% of all pediatric AML in united states
Estimated 600-800 new cases per year in United States
Our patint: 6 y/o
13. Clinical manifestations
Br J Haematol. 2006 Nov;135(4):450-74
Blood. 2009 Feb 26;113(9):1875-91
N Engl J Med. 1993;329(3):177.
13
General
Symptoms related to complications of pancytopenia
(anemia, neutropenia, and thrombocytopenia)
Weakness and easy fatigue, infections, Hemorrhage
Leukostasis (when blast count > 50,000/L)
Dyspnea, chest pain, headache, blurred vision, altered mental status
Especially with APL
Disseminated intravascular coagulation (DIC)
Life-threatening complications: intracerebral or pulmonary hemorrhage
10-20% incidence of early fatal hemorrhagic
Requires emergent therapy
14. Acute Promyelocytic Leukemia (APL)
N Engl J Med. 1997;337(15):1021.
Blood. 2011;118(5):1248.
14
Diagnosis of APL is confirmed by the identification of the
t(15;17) PML-RARα fusion gene
Most severe (but also most treatable) type of AML
Median survival of less than one month
Treatment of APL differs from other types of AML
ATRA/As2O3 + anthracycline-based chemotherapy
CR rates: 85-90%
ATRA: all-trans retinoic acid
15. Effect of ATRA on APL cells
15
As a differentiation agent
Addition of ATRA or As2O3 results in degradation of the PML-RARα fusion
protein and release of the corepressors
Allows the normal RARα to bind to target genes and promote transcription
Lead to differentiation of the promyelocyte to a mature granulocyte
16. TPOG-APL-2001
16
Induction Therapy (repeat q3w until CR)
ATRA 30mg/m2/d PO, BID, started D1 (<90 days)
Idarubicin 9mg/m2/d, IV 5-10 minutes D1-3
IT MTX D1
Consolidation Therapy (q4W x 3 cycles)
If ANC >1,000/mm3, platelet >100,000/mm3
Idarubicin 9mg/m2/d, IV 5-10 minutes D1-3
IT MTX D1
Probably needs prophylactic G-CSF
Maintenance Therapy (2 years)
ATRA 25mg/m2/d PO, BID, for 15 days every 3 months
6-MP 90mg/m2/d PO
MTX 15mg/m2/w PO
- If WBC <3,500/mm3, 6-MP and MTX 50% dose
- If WBC <2,500/mm3, discontinue 6-MP and MTX
Differentiation agent
Started immediately if suspected
17. Complications of treatment
Blood. 2009 Feb 26;113(9):1875-91
J Clin Oncol 2010 Aug 20;28(24):3872
17
APL differentiation syndrome (retinoic acid syndrome, RAS)
May be caused by ATRA or arsenic trioxide treatment
Pseudotumor cerebri
More common in children treated with ATRA
Therapy-related myeloid neoplasms (t-MNs)
Infrequent: 1.9%
Complications of treatment with arsenic trioxide
Leukocytosis: 50%
Prolonged QT interval
19. Differentiation syndrome (DS)
Blood. 1998;92(8):2712.
J Clin Oncol. 2000;18(13):2620.
Ann Intern Med. 1992;117(4):292.
19
Previously called "retinoic acid syndrome“ (RAS)
Caused by ATRA or As2O3 treatment during APL induction therapy
Not observed when ATRA/As2O3 are used in non-APL malignancies
Incidence:
2-27% with ATRA
30% with As2O3
Onset:
Median of 7 days (range 2-46 days) after treatment initiation
Potential life-threatening
20. Pathophysiology
J Oncol Pharm Pract 2012 18: 109 20
Three general theories have been proposed to explain the
infiltration of myeloid cells into the lung and other tissues:
Release of cytokines from differentiating myeloid cells that cause a
capillary leak syndrome
Sudden increase in differentiated myelocytes and neutrophils
Upregulation of the expression of cellular adhesion molecules, which
increase adherence to endothelial cells
21. Clinical presentation and diagnosis
J Clin Pharm Ther. 2008 Aug;33(4):331-8.
21
The diagnosis is made based on clinical features and findings in the
absence of other causes
At least three of the following signs and symptoms
Differential diagnosis: lung infection, sepsis, thromboembolism, and
heart failure
A rapid improvement with initiation of treatment supports the
diagnosis of differentiation syndrome
Symptoms and signs
Unexplained fever Pleural/pericardial effusions
Weight gain (Peripheral edema ) Hypotension
Respiratory distress Renal/hepatic dysfunction
Pulmonary infiltrates
22. Management of differentiation syndrome
Blood. 2009;113(9):1875.
J Natl Compr Canc Netw. 2006;4(1):37.
22
Principle: early recognition and aggressive management
Without treatment: high mortality 30%
With treatment: mortality 5%
improve ≤ 12 hours and complete resolution of symptoms ≤ 24 hours
Glucocorticoids
Given at the first suspicion of RAS appear to reduce morbidity and
mortality (in presence of any of symptoms)
Dexamethasone 10 mg q12h for at least 3 days until the complete
disappearance of symptoms and then tapered
23. Case discussion
23
Literature review Our patient
Cause
ATRA or As2O3 treatment during
APL induction therapy
ATRA 20mg QD, 10mg HS during
APL induction therapy
Onset
Median of 7 days
(range 2-46 days)
Day 2
• Pleural effusion
• WBC: 52800→ 96600/μL
Day 3
• Peripheral edema with BW gain
(25.8 28.8kg)
Day 9
• Persisted high fever at the regular time
(morning and night)
• Progressed increased CRP level although
antibiotics use
Symptoms
and signs
• Leukocytosis
• Unexplained fever
• Pleural/pericardial effusions
• Weight gain (Peripheral edema )
• Hypotension
• Respiratory distress
• Renal/hepatic dysfunction
• Pulmonary infiltrates
Outcome
A rapid improvement with initiation
of treatment
Day 2 Dexamethasone
Day 3 no pleural effusion, WBC decreased
Day 7 normal BW
24. Problem list
24
Whether ATRA should be continued or discontinued
when differentiation syndrome develops ?
Can we use ATRA as maintenance therapy in this patient ?
What are the predictive factors of DS ?
Do we need prophylaxis or what can we do if patient is
at high risk?
?
25. Literature review-1
25
Purpose
To examined the incidence, clinical course, and outcome of patients with
newly diagnosed APL who developed DS
Blood. 2000;95(1):90.
167 patient receive
ATRA for APL induction
44 (26%) developed RAS
• Onset
Median of 11 days of ATRA (range 2-47)
• WBC count
1450/μL (at diagnosis) 31000/μL (at develop RAS)
123 (74%) without RAS
26. Outcome of 44 patients with DS
Blood. 2000;95(1):90. 26
Resumed ATRA
19 (53%)
Not resumed ATRA
17 (47%)
1 death
Continued ATRA
8 (18%)
all syndrome resolved
with steroid
• 2 deaths definitely attributed to DS
• None of the patients who subsequently received ATRA as maintenance therapy
developed differentiation syndrome
3 recurred
(1 death, resumed
without steroid)
Discontinued ATRA
at the earliest signs of RAS
36 (82%)
44 patients with DS
27. Q & A
Blood. 2000;95(1):90.
Blood. 2009 Feb 26;113(9):1875-91
27
Whether ATRA should be continued or discontinued when
differentiation syndrome develops?
For most patients, ATRA can be safely continued as long as prompt treatment
with glucocorticoids is implemented
Temporary discontinuation of ATRA indicated only in case of severe DS
(renal failure, respiratory distress lack of response to dexamethasone)
Once symptoms have completely resolved, ATRA can be restarted, but under
the cover of steroids and closely monitor for signs and symptoms of DS
because the syndrome may recur
Can we use ATRA as maintenance therapy in this patient ?
Yes. DS is not observed when ATRA used as maintenance therapy for APL
28. Problem list
28
Whether ATRA should be continued or discontinued
when differentiation syndrome develops ?
Can we use ATRA as maintenance therapy in this patient ?
What are the predictive factors of DS ?
Do we need prophylaxis or what can we do if patient is
at high risk?
?
29. Literature review-2
29
A retrospective review
Patients
739 newly diagnosed APL patients treated with ATRA plus
idarubicin for induction therapy
Purpose
analyze the incidence, characteristics, prognostic factors, and outcome
Blood. 2009;113(4):775.
30. Results-incidence
Blood. 2009;113(4):775. 30
DS occurred in 183 patients (24.8%)
93 patients (12.6%) had severe DS
90 patients (12.2%) had moderate DS
Bimodal incidence of DS was observed,
with peaks occurring in the first and third
weeks after the start of ATRA therapy
More frequently in patients with a high
WBC at diagnosis
Signs and symptoms: Severe DS: ≥ 4 Moderate: 2-3
• Dyspnea
• Unexplained fever
• Weight gain ≥ 5 kg
• Unexplained hypotension
• Acute renal failure
• CXR: pulmonary infiltrates or
pleuropericardial effusion
Time to occurrence of DS
31. Results-characteristics
Blood. 2009;113(4):775. 31
The most frequent clinical manifestations of severe DS were dyspnea,
pulmonary infiltrates, edema, unexplained fever
Hypotension is more frequent in late severe DS than in early severe DS
(P= .007)
Clinical signs and symptoms of moderate and severe DS
Occurred ≤ 7 days > 7 days
32. Results-prognostic factors, and outcome
Blood. 2009;113(4):775.
32
Outcome and complications of DS
No DS
(n=556)
Moderate
(n =90)
Severe
(n=93)
P
Early severe
(n=50)
Late severe
(n=43)
P
Death during induction (%) 37 (7) 5 (6) 24 (26) < .001 20 (40) 4 (9) .001
Death due to DS (%) 0 (0) 0 (0) 10 (11) < .001 8 (16) 2 (5) .08
Thrombosis during induction (%) 18 (3) 3 (3) 9 (10) .008 5 (10) 4 (9) .91
Grade 3-4 hepatotoxicity (%) 24 (5) 5 (6) 11 (14) .01 5 (12) 6 (15) .65
Outcome
Severe DS was significantly associated with mortality (higher in early severe
DS), thrombosis, and hepatotoxicity
Factors OR (95% CI) of Severe DS P
WBC count > 5000 /μL 1.8 (1.1-2.7) .021
Creatinine > 1.4 mg/dL 5.8 (1.9-16.9) .004
Factors predicting severe DS
WBC > 5000/μL, abnormal serum creatinine level
33. Other potential risk factors for DS
33
Study N Incidence of DS Potential risk factors for DS
Blood.
2009;113(4):775.
739 25%
• WBC > 5000/μL (p= 0.021) for severe DS
• Scr > 1.4 mg/dL (p= 0.004) for severe DS
Leukemia.
2003;17(2):339-342
306 13%
• Sequential (18%) versus concomitant (9%)
chemotherapy (p= 0.035)
Leuk Res.
2010;34(4):545.
36 31%
• WBC ≥ 20000/μL (p= 0.025)
• BMI ≥ 30 (67%) versus BMI < 30 (19%)
(p= 0.012)
34. Literature review-3
34
Compare two trials (APL 93 and APL 2000) in patients with high WBC counts
to evaluated outcome improvement in such patients
J Clin Oncol. 2009 Jun 1;27(16):2668-76.
Prophylaxis of DS Treatment of DS
Early death
due to DS in
WBC > 10,000/μL
APL 93 X
Both receive dexamethasone
for treatment of DS
until resolution of symptoms
8/139 (6%)
APL 2000
If WBC > 10,000/μL
Dexamethaone 10 mg q12h
for 3-5 days
2/133 (1.5%)
35. Q & A
Blood. 2000;95(1):90.
Blood. 2009 Feb 26;113(9):1875-91
35
What are the predictive factors of DS ?
High WBC count
Abnormal serum creatinine level
BMI ≥ 30
Do we need prophylaxis or what can we do if patient is at high
risk?
Prophylactic glucocorticoids for patients with initial WBC > 10,000/μL
Suggested regimen: Dexamethasone 10 mg q12h for 3–5 days, followed by
2-week taper
Consider start chemotherapy immediately if hyperleukocytosis
37. Pseudotumor cerebri (PC)
J Neuroophthalmol. 2001;21(1):12.
Case Rep Oncol Med. 2012;2012:313057
37
PC is characterized by
Symptoms and signs of increased intracranial pressure
Headache: most common
Ocular signs: transient visual obscurations, diplopia
Papilledema: usually bilateral and symmetric, severity is associated with the risk of
permanent visual loss
N/V
But with normal cerebrospinal fluid composition and normal brain imaging
Epidemiology
Incidence: 1 per 100,000 /year
Predominantly affects obese women of childbearing age
Medications associated with PC: growth hormone, tetracycline, retinoids
38. ATRA associated pseudotumor cerebri
Case Rep Oncol Med. 2012;2012:313057 38
Exact pathogenesis has not been established
Onset
Median 14 days (range: 7 days-10 months) after initiate ATRA
Occurrence
Most often during induction therapy (78%)
Predominantly in the pediatric
Concurrent medications such as triazole antifungals may increase risk
Management
Temporary ATRA discontinuation
Diuretics– mannitol, glycerin, acetazolamide
Lumbar puncture
Analgesics
Corticosteroid
39. Common drug interactions with ATRA
39
ATRA is Metabolized by CYP isoenzymes (CYP2C8, CYP2C9, CYP3A4)
Concomitant use of drugs that affect CYP isoenzymes can lead to toxic ATRA
concentrations
Drug Severity Interaction
Tranexamic acid
Aminocaproic acid
aprotinin
Major Increased risk of thrombosis
Paclitaxel Major Increased risk of paclitaxel toxicity
Tetracycline Major Increased risk of pseudotumor cerebri
Fluconazole
Ketoconazole
Voriconazole
Moderate Increased risk of tretinoin toxicity
Methotrexate Moderate Increased hepatotoxicity
Glucocorticoids Moderate Decreased efficacy of tretinoin
40. Case discussion
PC associated with interaction of ATRA with fluconazole
Case Rep Oncol Med. 2012;2012:313057
J Pediatr Hematol Oncol. 2003 May;25(5):403-4.
40
Case 1 Case 2 Our patient
Patient 38 y/o female 4 y/o male 6 y/o female
Therapy ATRA 45mg/m2/d ATRA 45mg/m2/d ATRA 30mg/m2/d
PC onset
• On day 17
• 10 days after Fluconazole
400mg/d
• [induction]
• On day 21
• 1 day after Fluconazole
100mg/d
• [induction]
• On day 22
• 9 days after Fluconazole
250mg/d
• [induction]
Presentation
Headache, photosensitivity,
N/V, bilateral papilledema
CSF pressure: 300mmH2O
Headache, papilledema, N/V
CSF pressure > 200mmH2O
Visual diplopia, NV
Papilloedema
CSF study??
Management
Discontinue ATRA
Acetazolamide
Antiemetics and analgesics
Discontinue ATRA Discontinue ATRA
Acetazolamide, Mannitol
Dexamethasone
Resolution The next week 1 day after 5 days after
Rechallenge
ATRA
No recurrent
Recurred under concurrent
with fluconazole ?
2nd 75% dose: 2 days onset, headache, N/V
discontinued ATRA
3rd 30% dose: 3 days onset, headache
discontinued fluconazole, resolve within 24 h
41. Q & A
41
Can we use ATRA as maintenance therapy in this patient ?
Yes.
ATRA associated pseudotumor cerebri occurred most often during
induction therapy but also during consolidation and maintenance
therapy
Cases of successful rechallenge ATRA, and some rechallenge successful
with prophylactic acetazolamide (500 mg/day)
Increased risk of PC when concomitant use of other medications that
affect the cytochrome P-450 system (triazole antifungals)
Rechallenge without concomitant these drugs, or carefully monitor for
the side effects of ATRA
42. Summary
42
ATRA is an important component in the treatment of acute
promyelocytic leukemia
Use of ATRA can lead to several side effects such as differentiation
syndrome(DS) and pseudotumor cerebri (PC)
For differentiation syndrome
Prophylactic steroids can be given in patients with hyperleukocytosis
Steroids should be started immediately at earliest suspicion of DS
Temporary discontinuation of ATRA indicated only in case of severe DS
For pseudotumor cerebri
Concomitant use of drugs that affect CYP isoenzymes may increase risk of
ATRA associated PC (tetracyclines, triazole antifungals)